BridgeBio's acoramidis shows positive Phase 3 results for ATTR-CM, with an FDA PDUFA date set for November 29, 2024, and potential $500M milestone payment upon approval.
BridgeBio presented positive Phase I/II data for BBP-812, a gene therapy targeting Canavan disease, at the ESCGT meeting, showing potential to correct the ASPA gene and reduce toxic NAA levels.